Nurix Therapeutics (NRIX) EBIT Margin: 2019-2025
Historic EBIT Margin for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to -1,157.65%.
- Nurix Therapeutics' EBIT Margin fell 72382.00% to -1,157.65% in Q3 2025 from the same period last year, while for Aug 2025 it was -319.32%, marking a year-over-year increase of 2398.00%. This contributed to the annual value of -390.52% for FY2024, which is 18911.00% down from last year.
- Nurix Therapeutics' EBIT Margin amounted to -1,157.65% in Q3 2025, which was down 955.45% from -109.68% recorded in Q2 2025.
- In the past 5 years, Nurix Therapeutics' EBIT Margin registered a high of -87.25% during Q2 2023, and its lowest value of -1,157.65% during Q3 2025.
- Over the past 3 years, Nurix Therapeutics' median EBIT Margin value was -338.60% (recorded in 2023), while the average stood at -376.75%.
- As far as peak fluctuations go, Nurix Therapeutics' EBIT Margin soared by 41,877bps in 2023, and later crashed by 72,382bps in 2025.
- Over the past 5 years, Nurix Therapeutics' EBIT Margin (Quarterly) stood at -513.16% in 2021, then crashed by 20,467bps to -717.82% in 2022, then spiked by 41,877bps to -299.06% in 2023, then plummeted by 18,767bps to -486.73% in 2024, then slumped by 72,382bps to -1,157.65% in 2025.
- Its last three reported values are -1,157.65% in Q3 2025, -109.68% for Q2 2025, and -340.67% during Q1 2025.